This retrospective observational study, part of the EU-funded CARAMEL project, aims to develop and validate personalized cardiovascular disease (CVD) risk assessment models specifically designed for menopausal and perimenopausal women (ages 40-60). The study leverages Real World Data (RWD) collected from multiple international clinical partners, including electronic health records (EHR), diagnostic imaging data, and signal data.
The main objective is to improve the prediction of CVD precursors such as hypertension and dyslipidemia, as well as mid- and long-term risk of CVD events, through advanced artificial intelligence (AI) models. These models will be trained on multimodal data to capture complex, individualized risk trajectories that current risk calculators fail to address, particularly in women. Special focus is placed on under-researched, women-specific risk factors and their interactions with traditional predictors.
The study includes several research objectives: (1) predicting the onset of hypertension and dyslipidemia using EHR data; (2) modeling the long-term risk of fatal and non-fatal cardiovascular events and disease trajectories; (3) identifying novel imaging biomarkers from routine screening tests such as mammography, DXA, ultrasound, and cardiac MRI; (4) developing multimodal prediction models combining imaging and clinical data; (5) creating automated AI tools for imaging biomarker extraction; and (6) using signal data from cardiac devices to predict disease progression and events.
The study population consists of middle-aged women with retrospective data available across different health systems. The expected outcome is a validated set of stratified, personalized CVD risk models that can support targeted prevention strategies and enable more equitable, sex-specific care. This will contribute to reducing the burden of CVD in women and addressing critical gaps in early detection, clinical decision-making, and health policy.
This project has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No 101156210.
None
None
Participants are identified retrospectively from electronic health records, imaging archives, and device registries across multiple healthcare systems and countries
Other
Retrospective
Not listed
15
Trial groupsSee each trial group below.
Occurrence and Predicted Risk of Cardiovascular Disease (CVD) Events (fatal and non-fatal)
The study will retrospectively evaluate the occurrence of cardiovascular disease (CVD) events and develop predictive models to estimate individual risk profiles for such events. CVD events include both fatal and non-fatal occurrences such as myocardial infarction, stroke, heart failure, arrhythmias, and atherosclerotic disease. Events will be identified using structured electronic health records (EHR) and coded using ICD-10 classifications. Risk will be modeled using multimodal data sources (EHR, imaging, and signals) to predict short- and long-term outcomes, stratified by individual characteristics. The outcome integrates: Event-based measures: Time to first fatal or non-fatal CVD event. Risk-based measures: Individual predicted probabilities of experiencing a CVD event or precursor condition (e.g., hypertension, dyslipidemia) over different time frames.
RO1. Personalized risk prediction of CVD precursors
First observation of HT or DY registered in the EHR, registered as a diagnostic code, or as a laboratory result or test. These include: * Diagnosis of HT registered in the EHR with either of the following ICD10 codes: * I10 Essential (primary) hypertension * I11.0 Hypertensive heart disease with heart failure * I11.9 Hypertensive heart disease without heart failure * I12.0 Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease * I13.0 Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease * I13.1 Hypertensive heart and chronic kidney disease without heart failure * I13.2 Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease * Diagnosis of DY registered in the EHR with either of the following ICD10 codes: * E78.1 Pure hyperglyceridemia * E78.2 Mixed hyperlipidemia
RO2. Personalized Risk Prediction of CVD Events and CVD trajectories
The occurrence of CVD events, which will be classified in fatal (if they are registered as the cause of death) or not fatal (if they are not registered as cause of death). * Fatal CVD events include the following ICD codes registered in the EHR: * I10-16 Hypertensive disease * I20-25 Ischemic heart disease * I46-52 Arrhythmias and heart failure, excluding I51.4 (Myocarditis unspecified) * I60-69 Cerebrovascular diseases * I70-73 Atherosclerosis/AAA * Not fatal CVD events include only the following ICD codes: * I21-I23 Not fatal myocardial infarction * I60-69 Not-fatal stroke
RO3. Novel Imaging Biomarkers and Patterns for CVD Risk Assessment
Evaluates the predictive performance of multimodal models combining imaging features (e.g., cardiac MRI, DXA, digital mammography) and electronic health record (EHR) variables to estimate the mid- and long-term risk of cardiovascular events (CVD) in women aged 40-60. The endpoint is the first occurrence of a fatal or non-fatal CVD event after the imaging test, as documented in the EHR. The models will be compared against standard risk assessment tools (e.g., SCORE2).
RO4. Multimodal EHR and ImageBased CVD Prediction Models
The occurrence of CVD events, which will be classified in fatal (if they are registered as the cause of death) or not fatal (if they are not registered as cause of death). * Fatal CVD events include the following ICD codes registered in the EHR: * I10-16 Hypertensive disease * I20-25 Ischemic heart disease * I46-52 Arrhythmias and heart failure, excluding I51.4 (Myocarditis unspecified) * I60-69 Cerebrovascular diseases * I70-73 Atherosclerosis/AAA * Not fatal CVD events include only the following ICD codes: * I21-I23 Not fatal myocardial infarction * I60-69 Not-fatal stroke
Click on the lead sponsor to view all of their trials.
Hospital Universitario Virgen Macarena
Lead sponsor
VISUAL INTERACTION & COMMUNICATION TECHNOLOGIES - VICOMTECH
Collaborator
Clinic for Cardiovascular Diseases Magdalena
Collaborator
Biokeralty Research Institute
Collaborator
Keralty SAS. Colombia
Collaborator
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Collaborator
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborator
University of Dublin, Trinity College
Collaborator
TREE Technology S.A.
Collaborator
Dublin City University
Collaborator
Tampere University
Collaborator
Ben-Gurion University of the Negev
Collaborator
Biogipuzkoa Health Research Institute
Collaborator
Vilnius University Hospital Santaros Klinikos
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
